Letter to the Editor: Microbial metabolites and immune regulation in inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease

doi:10.3748/wjg.118010

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 30

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Aug 14, 2026; 32(30): 118010
Published online Aug 14, 2026. doi: 10.3748/wjg.118010

Letter to the Editor: Microbial metabolites and immune regulation in inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease

Zi-Ke Chen, Min Shi, Yuan-Bin Wu, Jia-Wei Zhao, Yu-Gang Wang

Zi-Ke Chen, Min Shi, Jia-Wei Zhao, Yu-Gang Wang, Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China

Zi-Ke Chen, Min Shi, Jia-Wei Zhao, Yu-Gang Wang, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China

Zi-Ke Chen, Min Shi, Jia-Wei Zhao, Yu-Gang Wang, Key Laboratory for Translational Research and Innovative Therapeutics of Gastrointestinal Oncology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China

Yuan-Bin Wu, Department of Emergency Medicine, The Seventh Medical Center, Chinese PLA General Hospital, Beijing 100700, China

Co-first authors: Zi-Ke Chen and Min Shi.

Co-corresponding authors: Jia-Wei Zhao and Yu-Gang Wang.

Author contributions: Chen ZK and Shi M wrote the original draft as co-first authors; Wu YB assisted in manuscript writing, literature retrieval and literature collection; Zhao JW and Wang YG conceived the article and revised the final draft as the co-corresponding authors; all of the authors read and approved the final version of the manuscript to be published.

AI contribution statement: ChatGPT is only used for language polishing, grammar correction, translation assistance, and improving readability. The entire or any part of the main content (abstract, introduction, materials and methods, results, discussion, and conclusion) of this manuscript is not generated by artificial intelligence. The main scientific content of this paper was written, reviewed, and finalized by the author themselves.

Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.

Corresponding author: Yu-Gang Wang, MD, PhD, Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai 200336, China. wang_yugang@sina.com

Received: December 23, 2025
Revised: January 27, 2026
Accepted: February 28, 2026
Published online: August 14, 2026
Processing time: 214 Days and 13.1 Hours

Core Tip

Core Tip: This letter builds on the important review by Sokal-Dembowska et al and further emphasizes the necessity to delve into the functional consequences of alterations in the microbial metabolome, as well as the complexity of Th17/Treg immune regulation in the gut-liver axis between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease. Specifically, this article focuses on elaborating how metabolites from specific gut microbiota and pathogenic Th17 cell subsets promote liver damage, and further discusses the translational medical significance of novel interleukin-23 targeted therapeutic strategies and sphingosine-1-phosphate receptor modulators.